|
Andreas Marti
Unit Head ATMP3
Swissmedic
Berne
Switzerland
|
Andreas Marti received his PhD in 1995 in oncology research at the University of Bern, Switzerland. After several years of research in academia and in the pharma industry, he joined in 2003 the Swiss Agency for Therapeutic Products, Swissmedic, to regulate gene therapy products in Switzerland. Currently he is head of the ATMP3 Unit which is responsible for the clinical and preclinical assessment of cell and gene therapy products, GMO products and nucleic acid products.